IL4R and asthma: Dupilumab, an anti-IL4Rα, was approved in Europe in 2017 for atopic dermatitis and in 2019 for T2 asthma, while the anti-IL-5Rα benralizumab was approved for eosinophilic asthma in 2018 [32].